Net sales during the period amounted to SEK 0 thousand (0)
Earnings after financial items amounted to SEK ?10,255 thousand (?7,724)
Earnings per share before and after dilution amounted to SEK ?0.27 (?0.41)
Financial information for January - June 2019
Net sales during the period amounted to SEK 0 thousand (0)
Earnings after financial items amounted to SEK ?21,841 thousand (?17,348)
Earnings per share before and after dilution amounted to SEK ?0.58 (?0.92)
The balance sheet total amounted to SEK 215,418 thousand (77,617) at the end of the period
Cash and cash equivalents amounted to SEK 210,315 thousand (75,913) at the end of the period
Significant events during the period January ? March 2019
In March, the company initiated a new drug project in the field of pain ? TrkA-NAM
The company was represented at the International Conference on Alzheimer's & Parkinson's Diseases, where it made two presentations
Significant events during the period April ? June 2019
In May, the company chose to redirect the drug candidate ACD855 from cognitive dysfunction to an eye indication and ACD856 is now the primary drug candidate for cognitive dysfunction
At the annual general meeting on May 22, 2019, the company resolved to issue a share options program targeted at the company's Board of Directors
Significant events following the end of the interim period
No significant events have taken place since the end of the interim period.
This is information that AlzeCure AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below at 09.00 am CET on August 22, 2019.
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer's disease. The company is listed on Nasdaq First North Premier and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson's disease. The company also has a project in the field of pain in early preclinical phase ? TrkA-NAM. FNCA Sweden AB is the company's certified adviser: contact +46(0)8-528 00 399, [email protected]. For further information, please visit our website at www.alzecurepharma.se.
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at...
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...